Quality of health in survivors of childhood acute myeloid leukemia treated with chemotherapy only: a NOPHO-AML study.

2.50
Hdl Handle:
http://hdl.handle.net/2336/227501
Title:
Quality of health in survivors of childhood acute myeloid leukemia treated with chemotherapy only: a NOPHO-AML study.
Authors:
Molgaard-Hansen, Lene; Glosli, Heidi; Jahnukainen, Kirsi; Jarfelt, Marianne; Jónmundsson, Guðmundur K; Malmros-Svennilson, Johan; Nysom, Karsten; Hasle, Henrik
Citation:
Pediatr. Blood Cancer 2011, 57(7):1222-9
Issue Date:
15-Dec-2011
Abstract:
BACKGROUND: More than 60% of children with acute myeloid leukemia (AML) become long-term survivors, and approximately 50% are cured with chemotherapy only. Limited data exist about their long-term morbidity and social outcomes. The aim of the study was to compare the self-reported use of health care services, health experience, social outcomes, and lifestyle behavior of AML survivors with that of their sibling controls. METHODS: This population-based study included 138 children treated for AML according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO)-AML-84, -88, and -93 trials, and alive by June 30, 2007. Patients treated with hematopoietic stem cell transplantation (HSCT) or relapse were not included. Altogether, 102 (74%) survivors and 91% of their siblings completed a questionnaire. RESULTS: The median follow-up was 11 (range 4-25) years after diagnosis. AML survivors had no increased rate of hospitalization compared with sibling controls, but were more often receiving prescription drugs, especially for asthma (23% vs. 9%, P = 0.03). Self-reported health experience was excellent or very good in 77% and comparable with that of siblings. Educational achievement, employment, and marital status were comparable in the two groups. Among surviving AML patients, 23% were current smokers and 24% of their siblings were current smokers. CONCLUSIONS: The self-reported health of children treated on NOPHO-AML protocols without HSCT was good, and their use of health care services was limited. Reported health and social outcomes were comparable to those of their siblings. Many survivors were smoking which may increase the risk of late effects.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field.
Additional Links:
http://dx.doi.org/10.1002/pbc.22931
Rights:
Archived with thanks to Pediatric blood & cancer

Full metadata record

DC FieldValue Language
dc.contributor.authorMolgaard-Hansen, Leneen_GB
dc.contributor.authorGlosli, Heidien_GB
dc.contributor.authorJahnukainen, Kirsien_GB
dc.contributor.authorJarfelt, Marianneen_GB
dc.contributor.authorJónmundsson, Guðmundur Ken_GB
dc.contributor.authorMalmros-Svennilson, Johanen_GB
dc.contributor.authorNysom, Karstenen_GB
dc.contributor.authorHasle, Henriken_GB
dc.date.accessioned2012-06-05T10:59:56Z-
dc.date.available2012-06-05T10:59:56Z-
dc.date.issued2011-12-15-
dc.date.submitted2012-06-05-
dc.identifier.citationPediatr. Blood Cancer 2011, 57(7):1222-9en_GB
dc.identifier.issn1545-5017-
dc.identifier.pmid22095929-
dc.identifier.doi10.1002/pbc.22931-
dc.identifier.urihttp://hdl.handle.net/2336/227501-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field.en_GB
dc.description.abstractBACKGROUND: More than 60% of children with acute myeloid leukemia (AML) become long-term survivors, and approximately 50% are cured with chemotherapy only. Limited data exist about their long-term morbidity and social outcomes. The aim of the study was to compare the self-reported use of health care services, health experience, social outcomes, and lifestyle behavior of AML survivors with that of their sibling controls. METHODS: This population-based study included 138 children treated for AML according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO)-AML-84, -88, and -93 trials, and alive by June 30, 2007. Patients treated with hematopoietic stem cell transplantation (HSCT) or relapse were not included. Altogether, 102 (74%) survivors and 91% of their siblings completed a questionnaire. RESULTS: The median follow-up was 11 (range 4-25) years after diagnosis. AML survivors had no increased rate of hospitalization compared with sibling controls, but were more often receiving prescription drugs, especially for asthma (23% vs. 9%, P = 0.03). Self-reported health experience was excellent or very good in 77% and comparable with that of siblings. Educational achievement, employment, and marital status were comparable in the two groups. Among surviving AML patients, 23% were current smokers and 24% of their siblings were current smokers. CONCLUSIONS: The self-reported health of children treated on NOPHO-AML protocols without HSCT was good, and their use of health care services was limited. Reported health and social outcomes were comparable to those of their siblings. Many survivors were smoking which may increase the risk of late effects.en_GB
dc.description.sponsorshipA. P. Moller Foundation for the Advancement of Medical Science Aarhus University Hospital Research Initiative Foundation Aase and Ejnar Danielsen Foundation Anders Hasselbalch Foundation Bent Bogh and wife Inge Bogh Foundation Carl J. Beckers Foundation Dagmar Marshall Foundation Danish Cancer Society Danish Childhood Cancer Foundation Danish Graduate School in Clinical Oncology Eva and Henry Fraenkel Foundation Frode V. Nyegaard and Wife Foundation Johannes Fogh-Nielsen and wife Ella Fogh-Nielsen Grant Karen Elise Jensen Foundation Kurt Bonnelycke and wife Grethe Bonnelycke Foundation M. Brogaard and Wife Foundation Max and Anna Friedmann Grant Meta and Haakon Bagger Foundation Oticon Foundation Otto Christensen Foundation Simon Fougner Hartmann and Family Foundation Sophus Jacobsen and wife Astrid Jacobsen Foundation Swedish Childhood Cancer Foundation Thora and Viggo Grove Grant University of Aarhusen_GB
dc.language.isoenen
dc.publisherWileyen_GB
dc.relation.urlhttp://dx.doi.org/10.1002/pbc.22931en_GB
dc.rightsArchived with thanks to Pediatric blood & canceren_GB
dc.subject.meshAdolescenten_GB
dc.subject.meshAdulten_GB
dc.subject.meshAge of Onseten_GB
dc.subject.meshAntineoplastic Combined Chemotherapy Protocolsen_GB
dc.subject.meshChilden_GB
dc.subject.meshChild, Preschoolen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshFollow-Up Studiesen_GB
dc.subject.meshHealth Statusen_GB
dc.subject.meshHumansen_GB
dc.subject.meshInfanten_GB
dc.subject.meshInfant, Newbornen_GB
dc.subject.meshLeukemia, Myeloid, Acuteen_GB
dc.subject.meshMaleen_GB
dc.subject.meshQuality of Lifeen_GB
dc.subject.meshQuestionnairesen_GB
dc.subject.meshSurvivorsen_GB
dc.subject.meshYoung Adulten_GB
dc.titleQuality of health in survivors of childhood acute myeloid leukemia treated with chemotherapy only: a NOPHO-AML study.en
dc.typeArticleen
dc.contributor.departmentDepartment of Pediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark. lene.molgaard@dadlnet.dken_GB
dc.identifier.journalPediatric blood & canceren_GB

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.